Basket | Login | Register

 
 
 
 

Clinical trials by country

Phase III trials

Belgium

  1. GRADUATE 2

Bulgaria

  1. BREXPIPRAZOLE
  2. 17-AVP-786-305 (planned)

Croatia

  1. GRADUATE 2

Czech Republic

  1. 17-AVP-786-305 (planned)

Denmark

  1. GRADUATE 2

Finland

  1. GRADUATE 2

France

  1. GAIN
  2. GRADUATE 1
  3. LO-MAPT
  4. 17-AVP-786-305

Germany

  1. GRADUATE 1

Hungary

  1. GRADUATE 1
  2. 17-AVP-786-305

Italy

  1. GRADUATE 1
  2. 17-AVP-786-305

Lithuania

  1. GRADUATE 1

Netherlands

  1. GAIN (planned)
  2. GRADUATE 2

Poland

  1. GAIN
  2. GRADUATE 2
  3. 17-AVP-786-305 (planned)

Portugal

  1. GRADUATE 2

Russia

  1. GRADUATE 1

Serbia

  1. BREXPIPRAZOLE

Spain

  1. BREXPIPRAZOLE
  2. GAIN
  3. GRADUATE 1
  4. GRADUATE 2
  5. 17-AVP-786-305

Sweden

  1. GRADUATE 2

Turkey

  1. GRADUATE 2

Ukraine

  1. BREXPIPRAZOLE

UK

  1. GAIN (planned)
  2. GRADUATE 2
  3. NorAD
  4. SYMBAD
  5. 17-AVP-786-305

 

 
 

Last Updated: Thursday 21 November 2019

 

 
  • Acknowledgements

    Alzheimer Europe's Clinical Trial Watch received funding under an operating grant from the European Union’s Health Programme (2014–2020).
  • European Union
 
 

Options